Primary non-Hodgkin lymphoma of the small bowel.
OBJECTIVE
To clarify the natural history of primary lymphoma of the small bowel and identify preferred treatments for it.


METHODS
A retrospective analysis of 61 patients with primary lymphoma of the small bowel was performed. The Ann Arbor stages were I in 20 patients, II in 28, and IV in 13. After resection or biopsy, 15 patients were treated with radiation therapy, 26 with chemotherapy, and 16 with combined-modality therapy. Four patients underwent no adjuvant treatment after resection.


RESULTS
The actuarial 10-year overall survival and relapse-free survival for the patients with intermediate- and high-grade lymphoma were 47% and 53%, respectively. For the patients with low-grade lymphoma, these rates were 81% and 62%. For patients who underwent radiation therapy, combined-modality therapy, or chemotherapy, the recurrence rates inside the abdomen or pelvis were one of 12, two of 15, and five of 20, respectively, and those outside the abdomen or pelvis were four of 12, one of 15, and zero of 20, respectively. Four of the five abdominopelvic recurrences of disease in the chemotherapy group were among the nine patients who had Ann Arbor stage II disease.


CONCLUSIONS
Chemotherapy lowered the recurrence rate outside the abdomen or pelvis. Patients with stage II disease may benefit most from radiation therapy.
Ha
C S
CS
Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Cho
M J
MJ
Allen
P K
PK
Fuller
L M
LM
Cabanillas
F
F
Cox
J D
JD
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000453:epidemiology* / Q000628:therapy; D007421:Intestine, Small; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents